A detailed history of Altrinsic Global Advisors LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Altrinsic Global Advisors LLC holds 182,734 shares of IONS stock, worth $6.96 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
182,734
Previous 187,831 2.71%
Holding current value
$6.96 Million
Previous $8.95 Million 18.23%
% of portfolio
0.34%
Previous 0.43%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$40.06 - $51.86 $204,185 - $264,330
-5,097 Reduced 2.71%
182,734 $7.32 Million
Q2 2024

Aug 14, 2024

SELL
$36.45 - $47.7 $256,352 - $335,474
-7,033 Reduced 3.61%
187,831 $8.95 Million
Q1 2024

May 14, 2024

SELL
$42.03 - $53.55 $600,524 - $765,122
-14,288 Reduced 6.83%
194,864 $8.45 Million
Q4 2023

Feb 14, 2024

SELL
$43.39 - $51.63 $3.6 Million - $4.29 Million
-83,032 Reduced 28.42%
209,152 $10.6 Million
Q3 2023

Nov 14, 2023

SELL
$38.5 - $47.13 $608,531 - $744,936
-15,806 Reduced 5.13%
292,184 $13.3 Million
Q2 2023

Aug 14, 2023

SELL
$34.73 - $43.33 $496,326 - $619,229
-14,291 Reduced 4.43%
307,990 $12.6 Million
Q1 2023

May 15, 2023

BUY
$33.58 - $41.2 $104,333 - $128,008
3,107 Added 0.97%
322,281 $11.5 Million
Q4 2022

Feb 14, 2023

BUY
$37.12 - $46.52 $5.86 Million - $7.35 Million
157,928 Added 97.94%
319,174 $12.1 Million
Q3 2022

Nov 14, 2022

SELL
$36.54 - $48.66 $921,100 - $1.23 Million
-25,208 Reduced 13.52%
161,246 $7.13 Million
Q2 2022

Aug 15, 2022

SELL
$31.71 - $43.0 $688,233 - $933,272
-21,704 Reduced 10.43%
186,454 $6.9 Million
Q1 2022

May 16, 2022

SELL
$29.88 - $37.04 $5.71 Million - $7.08 Million
-191,234 Reduced 47.88%
208,158 $7.71 Million
Q4 2021

Feb 14, 2022

SELL
$25.61 - $35.1 $1.17 Million - $1.6 Million
-45,495 Reduced 10.23%
399,392 $12.2 Million
Q3 2021

Nov 15, 2021

SELL
$33.54 - $40.55 $380,310 - $459,796
-11,339 Reduced 2.49%
444,887 $14.9 Million
Q2 2021

Aug 13, 2021

BUY
$34.54 - $47.25 $524,040 - $716,877
15,172 Added 3.44%
456,226 $18.2 Million
Q1 2021

May 14, 2021

BUY
$42.51 - $63.78 $4.18 Million - $6.27 Million
98,280 Added 28.67%
441,054 $19.8 Million
Q4 2020

Feb 16, 2021

SELL
$45.3 - $60.27 $53,363 - $70,998
-1,178 Reduced 0.34%
342,774 $19.4 Million
Q3 2020

Nov 16, 2020

BUY
$47.45 - $62.95 $144,817 - $192,123
3,052 Added 0.9%
343,952 $16.3 Million
Q2 2020

Aug 14, 2020

SELL
$46.85 - $61.05 $371,707 - $484,370
-7,934 Reduced 2.27%
340,900 $20.1 Million
Q1 2020

May 14, 2020

BUY
$41.6 - $63.4 $3.21 Million - $4.9 Million
77,266 Added 28.45%
348,834 $16.5 Million
Q4 2019

Feb 14, 2020

SELL
$53.85 - $65.27 $949,375 - $1.15 Million
-17,630 Reduced 6.1%
271,568 $16.4 Million
Q3 2019

Nov 14, 2019

BUY
$59.06 - $72.15 $6.52 Million - $7.96 Million
110,384 Added 61.73%
289,198 $17.3 Million
Q2 2019

Aug 14, 2019

SELL
$62.09 - $86.14 $3.65 Million - $5.07 Million
-58,831 Reduced 24.76%
178,814 $11.5 Million
Q1 2019

May 14, 2019

SELL
$52.92 - $81.17 $15.4 Million - $23.6 Million
-290,614 Reduced 55.01%
237,645 $19.3 Million
Q4 2018

Feb 14, 2019

BUY
$43.37 - $59.54 $175,258 - $240,601
4,041 Added 0.77%
528,259 $28.6 Million
Q3 2018

Nov 14, 2018

BUY
$42.88 - $53.7 $115,904 - $145,151
2,703 Added 0.52%
524,218 $27 Million
Q2 2018

Aug 13, 2018

BUY
$40.53 - $50.7 $3.22 Million - $4.03 Million
79,390 Added 17.96%
521,515 $21.7 Million
Q1 2018

May 14, 2018

SELL
$44.08 - $55.05 $988,934 - $1.24 Million
-22,435 Reduced 4.83%
442,125 $19.5 Million
Q4 2017

Feb 13, 2018

SELL
$50.3 - $64.39 $7.04 Million - $9.01 Million
-139,895 Reduced 23.14%
464,560 $23.4 Million
Q3 2017

Nov 14, 2017

BUY
$45.56 - $59.57 $27.5 Million - $36 Million
604,455
604,455 $30.6 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.41B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Altrinsic Global Advisors LLC Portfolio

Follow Altrinsic Global Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altrinsic Global Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Altrinsic Global Advisors LLC with notifications on news.